Myeloproliferative Neoplasms (MPN)

For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.

Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review.

A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.

Researchers identified distinct patterns of epigenetic dysregulation in myeloproliferative neoplasms.

Budd-Chiari syndrome and myeloproliferative neoplasms (MPNs) are rare, which means available data are limited.

A recent survey of patients with myeloproliferative neoplasms found integrative medicine interventions improved symptom burden, fatigue, depression, and improved quality of life.